From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Synergy Between Moderate Alcohol Use and HRT for Breast Cancer Risk

Postmenopausal women who took hormones and who drank alcohol were at increased risk for breast cancer.

Alcohol consumption and hormone replacement therapy each elevate breast cancer risk. In this prospective cohort study, investigators from the Nurses' Health Study followed 44,186 postmenopausal registered nurses without cancer to further examine the effects of these risk factors.

During a maximum 16 years of follow-up (557,984 person-years), invasive breast cancer developed in 1722 women. In analyses that were adjusted for HRT use and other risk factors for breast cancer, 10-19.9 g of alcohol daily (1 drink) and ≥20 g of alcohol daily (≥2 drinks) were associated with increased risk for breast cancer (relative risks compared with no alcohol use, 1.2 and 1.3, respectively). Compared with no HRT use, current HRT use of <5 years and ≥5 years also increased breast cancer risk (RRs, 1.4 and 1.5, respectively). The risk for breast cancer was higher for HRT users who drank alcohol than for nonusers who did not drink: At 5-9.9 g and 10-19.9 g alcohol daily, ≥5 years of HRT conferred RRs of 1.6 and 1.9, respectively; at ≥20 g daily, <5 years and ≥5 years of HRT conferred RRs of 2.1 and 2, respectively.

Comment: Results from observational studies are consistent on this point: Moderate drinking increases risk for breast cancer. The findings of this study are biologically plausible, as concomitant HRT and alcohol use elevates estrogen levels. HRT users should be aware of this interaction when they make decisions about drinking alcohol and about taking HRT.

— Richard Saitz, MD, MPH

Published in Journal Watch General Medicine December 27, 2002

Citation(s):

Chen WY et al. Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer. Ann Intern Med 2002 Nov 19; 137:798-804.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2002. Massachusetts Medical Society. All rights reserved.